Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE)
Launched by FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD · Jan 7, 2021
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The IMMUNOSTROKE study is looking at how the immune system and inflammation affect patients who have suffered an ischemic stroke, which is a type of stroke caused by a blockage in the blood vessels of the brain. The goal is to understand how these factors change during treatment that aims to restore blood flow, and how they relate to recovery in terms of physical and thinking abilities after the stroke.
To participate in this trial, individuals must be experiencing an ischemic stroke and be eligible for specific treatments that help restore blood flow, such as medications or procedures. However, certain conditions may prevent someone from joining, including having a brain bleed, severe prior neurological issues, or specific medical devices that can interfere with imaging tests. This study is not yet recruiting participants, but it aims to provide valuable insights that could improve stroke treatment and recovery in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Presenting an ISCHEMIC STROKE for which reperfusion treatment is indicated according to European and North American recommendations (intraveinous thrombolysis or mechanical thrombectomy or a combination of both)
- Exclusion Criteria:
- • Contraindication to performing a cerebral MRI (claustrophobia, pacemaker or other implantable device contraindicating the performance of MRI)
- • Intracranial haemorrhage associated with AIC on initial imaging
- • Immunosuppressive treatment or corticosteroid therapy on admission of the patient
- • Pre-existing neurological disability limiting the neurological assessment to 3 months (mRS\>2 on admission)
- • Dementia known and diagnosed pre-existing at ischemic stroke
- • Absolute or relative contraindication to gadolinium injection (history of true allergic reaction or intolerance to gadobutrol, renal failure with creatinine clearance \<15mL/min, pregnant or breastfeeding woman).
About Fondation Ophtalmologique Adolphe De Rothschild
The Fondation Ophtalmologique Adolphe de Rothschild is a leading French institution dedicated to advancing ophthalmic research and patient care. Renowned for its commitment to innovation in eye health, the foundation conducts cutting-edge clinical trials aimed at improving treatments for various ocular conditions. With a multidisciplinary team of experts, the foundation collaborates with academic and industry partners to enhance understanding of eye diseases and develop novel therapeutic solutions, ultimately striving to improve patient outcomes and quality of life in ophthalmology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials